Yersinia pestis (plague) vaccines

Expert Opinion on Biological Therapy

Volumn 4, Issue 6, 2004, Pages 965-973

  Titball, Richard W ^a   Williamson, E Diane ^a  

^a DEFENCE SCIENCE AND TECHNOLOGY LABORATORY   (United Kingdom)

Author keywords

Plague; Vaccine; Yersinia pestis

Indexed keywords

BACTERIAL VACCINE; NAKED DNA; UNCLASSIFIED DRUG; YERSINIA PESTIS VACCINE;

ANIMAL EXPERIMENT; FEVER; HEADACHE; HUMAN; IMMUNIZATION; LYMPHADENOPATHY; MALAISE; MOUSE; NONHUMAN; PLAGUE; REVIEW; YERSINIA PESTIS;

ANIMALS; ANTIGENS, BACTERIAL; GUINEA PIGS; HUMANS; MICE; MUTATION; PLAGUE VACCINE; VACCINES; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; YERSINIA PESTIS;

ANIMALIA; BACTERIA (MICROORGANISMS); YERSINIA; YERSINIA PESTIS;

EID: 3042601140     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.6.965     Document Type: Review

References (84)

1. DUPLAIX N: Fleas - the lethal leapers. National Geographic (1988) 173:672-694.
2. PERRY RD, FETHERSTON JD: Yersinia pestis - etiologic agent of plague. Clin Microbiol. Rev. (1997) 10:35-66. This reference provides an excellent overview of the biology of Y. pestis.
3. INGLESBY TV, DENNIS DT, HENDERSON DA et al.: Plague as a biological weapon - medical and public health management. JAMA (2000) 285:2281-2290.
4. ANON: Prevention of plague: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. (1996) 45:1-15.
5. ANON: Human Plague in 1998 and 1999. World Health Organ. Wkly Epidemiol. Rec. (2000) 75:337-344.
6. FRITZ CL, DENNIS DT, TIPPLE MA et al.: Surveillance for pneumonic plague in the United States during an international emergency: a model for control of imported emerging disease. Emerg. Infect. Dis. (1996) 2:30-36.
7. DAVEY S: Removing Obstacles to Healthy Development. Leotsakos A (Ed.), World Health Organization, Switzerland (1999).
8. st Edition). World Health Organisation, Geneva (1970). This reference provides an overview of the use of Y. pestis as a biological weapon.
9. BRUBAKER RR: Factors promoting acute and chronic diseases caused by yersiniae. Clin. Microbiol. Rev. (1991) 4:309-324. This reference provides a review of virulence mechanisms of Yersinia.
10. CAVANAUGH DC: Specific effect of temperature upon transmission of the plague bacillus by the oriental rat flea Xenopsylla cheopis. Am. J. Trop. Med. Hyg. (1971) 20:264-272.
11. DU YD, ROSQVIST R, FORSBERG A: Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect. Immun. (2002) 70:1453-1460.
12. CAVANAUGH DC, RANDALL R: The role of multiplication of Pasteurella pestis in mononuclear phagocytes in the pathogenesis of flea-borne plague. J. Immunol. (1959) 83:348-363.
13. OYSTON PCF, DORRELL N, WILLIAMS K et al.: The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis. Infect. Immun. (2000) 68:3419-3425.
14. WILLIAMS RC, GEWURZ H, QUIE PG: Effects of fraction 1 from Yersinia pestis on phagocytosis in vitro. J. Infect. Dis. (1972) 126:235-241.
15. POLAND JD, BARNES AM: Plague. In: CRC Handbook Series in Zoonoses. Section A. Bacterial, Riekettsial, and Mycotic Diseases. Steele JH (Ed.), CRC Press, Boca Raton, FL, USA (1979):515-597.
16. MEYER KF: Pneumonic plague. Bacteriol. Rev. (1961) 35:249-261.
17. CHRISTIE AB, CORBEL MJ: Plague and other yersinial diseases. In: Topley and Wilson's Principles of Bacteriology, Virology and Immunity. Smith GR (Ed), Edward Arnold, London, UK (1990):399-410.
18. TITBALL RW, ELEY S, WILLIAMSON ED, DENNIS DT: Plague. In: Vaccines. Plotkin SA, Orenstein WA, Zorab R (Eds), WB Saunders Company, Philadelphia, USA (1999):734-742. This reference provides an up-to-date and detailed review of existing plague vaccines and summarises approches to new vaccines.
19. MEYER KF, FOSTER LE: Measurement of protective serum antibodies in human volunteers inoculated with plague prophylactics. Stanford Med. Bull. (1948) 6:75-79.
20. BARTELLONI PJ, MARSHALL JD, CAVANAUGH DC: Clinical and serological responses to plague vaccine. Mil. Med. (1973) 138:720-722.
21. MEYER KF: Effectiveness of live of killed plague vaccines in man. Bull. World Health Organ. (1970) 42:653-666.
22. VON METZ E, EISLER DM, HOTTLE GA: Immunogenicity of plague vaccines in mice and guinea pigs. Appl. Microbiol. (1971) 22:84-88.
23. MEYER KF, SMITH G, FOSTER LE, MARSHALL JD, CAVANAUGH DC: Plague immunization. IV. Clinical reactions and serologic response to inoculations of Haffekine and freeze-dried plague vaccine. J. Infect. Dis. (1974) 129:S30-S36.
24. BRUBAKER RR: Mutation rate to nonpigmentation in Pasturella pestis. J. Bacteriol. (1969) 98:1404-1406.
25. RUSSELL P, ELEY SM, HIBBS SE et al.: A comparison of plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine (1995) 13:1551-1556.
26. MEYER KF, CAVANAUGH DC, BARTELLONI PJ, MARSHALL JD: Plague immunization. I. Past and present trends. J. Infect. Dis. (1974) 129:S13-S18.
27. NAUMOV AV, LEDVANOV MY, DROZDOV IG: Plague immunology. Russian Research Anti-Plague Institute 'Microbe', Saratov, Russia (1992).
28. WILLIAMS JE, ALTIERI PL, BERMAN S, LOWENTHAL JP, CAVANAUGH DC: Potency of killed plague vaccines prepared from avirulent Yersinia pestis. Bull. World. Health. Organ. (1980) 58:753-756.
29. REISMAN RE: Allergic reactions due to plague vaccine. J. Allergy (1970) 46:49-56.
30. MARSHALL JDJ, BAKTELLONI PJ, CAVANAUGH DC, KADULL PJ, MEYER, KF: Plague immunization. II. Relation of adverse clinical reactions to multiple immunizations with killed vaccine. J. Infect. Dis. (1974) 129:S19-S25.
31. WILLIAMS JE, CAVANAUGH DC: Measuring the efficacy of vaccination in affording protection against plague. Bull World Health Organ. (1979) 57:309-313.
32. CAVANAUGH DC, ELISBERG BL, LLEWLLYN CH et al.: Plague immunisation. V. Indirect evidence for the efficacy of plague vaccine. J. Infect. Dis. (1974) 129:S37-S40.
33. BARNES AM: Surveillance and control of bubonic plague in the United States. Symp. Zool. Soc. Lond (1982) 50:237-270.
34. COHEN RJ, STOCKARD JL: Pneumonic plague in an untreated plague vaccinated individual. JAMA (1967) 202:365-366.
35. FRIEDLANDER AM, WELKOS SL, WORSHAM PL et al.: Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin. Infect. Dis. (1995) 21:S178-S181.
36. HOHMANN EL, OLETTA CA, KILLEEN KP, MILLER SI: phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect. Dis. (1996) 173:1408-1414.
37. DOUGAN G: The molecular-basis for the virulence of bacterial pathogens-implications for oral vaccine development. Microbiology (UK (1994) 140:215-224.
38. OCALLAGHAN D, MASKELL D, LIEW FY, EASMON CSF, DOUGAN G: Characterization of atomatic-dependent and purine-dependent Salmonella typhimurium - attenuation, persistence, and ability to induce protective immunity in Balb/C mice. Infect. Immun. (1988) 56:419-423.
39. SMITH BP, REINAGUERRA M, HOISETH SK et al.: Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am. J. Vet. Res. (1984) 45:59-66.
40. OYSTON PCF, RUSSELL P, WILLIAMSON ED, TITBALL RW: An aroA mutant of Yersinia pestis is attenuated in guinea-pigs, but virulent in mice. Microbiology (1996) 142:1847-1853.
41. WILLIAMS K, OYSTON PCF, DORRELL N et al.: Investigation into the role of the serine protease HtrA in Yersinia pestis pathogenesis. FEMS Microbiol. Lett. (2000) 186:281-286.
42. FLASHNER Y, MAMROUD E, TIDHAR A et al.: Generation of Yersiniapestis attenuated strains by signature-tagged mutagenesis in search of novel vaccine candidates. Infect. Immun. (2004) 72:908-915. This reference describes a recently isolated attenuated mutant of Y. pestis that could be exploited as a live vaccine against plague.
43. WILLIAMSON ED, ELEY SM, GRIFFIN KF et al.: A new improved subunit vaccine for plague: the basis of protection. FEMS Immunol. Med. Microbiol. (1995) 12:223-230. This reference details the protection afforded by an F1- and V-antigen subunit vaccine.
44. LEARY SEC, WILLIAMSON ED, GRIFFIN KF et al.: Active immunisation with V-antigen from Yersinia pestis protects against plague. Infect. Immun. (1995) 63:2854-2858.
45. ANDREWS GP, HEATH DG, ANDERSON GWJ, WELKOS SL, FRIEDLANDER AM: Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal challenge. Infect. Immun. (1996) 64:2180-2187.
46. MOTIN VL, NAKAJIMA R, SMIRNOV GB, BRUBAKER RR: Passive immunity to yersiniae mediated by antirecombinant V antigen and protein A-V fusion peptide. Infect. Immun. (1994) 62:4192-4201.
47. MOTIN VL, NEDIALKOV YA, BRUBAKER RR: V antigen-polyhistidine fusion peptide: binding to LcrH and active immunity against plague. Infect. Immun. (1996) 64:4313-4318.
48. UNE T, BRUBAKER RR: Roles of V antigen in promoting virulence and immunity in yersinia. J. Immunol. (1984) 133:2226-2230.
49. ROGGENKAMP A, GEIGER AM, LEITRITZ L, KESSLER A, HEESEMANN J: Passive immunity to infection with Yersinia spp mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect. Immun. (1997) 65:446-451.
50. TITBALL RW, HOWELLS AM, OYSTON PCF, WILLIAMSON ED: Expression of the Yersinia pestis capsular antigen (F1-antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun. (1997) 65:1926-1930.
51. HEATH DG, ANDERSON GWJ, MAURO JM et al.: Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine (1998) 16:1131-1137.
52. ANDERSON GWJ, HEATH DG, BOLT CR, WELKOS SL, FRIEDLANDER AM: Short- and long-term efficacy of single dose subunit vaccines against Yersinia pestis in mice. Am. J. Trop. Med. Hyg. (1998) 58:793-799.
53. WILLIAMSON ED, VESEY PM, GILLHESPY KJ et al.: An IgG1 titre to the F1 aud V antigens correlates with protection against plague in the mouse model. Clin. Exp. Immunol. (1999) 116:107-114.
54. ZAVIALOV AV, BERGLUND J, PUDNEY AF et al.: Structure and biogenesis of the capsular F1 antigen from Yersinia pestis: preserved folding energy drives fiber formation. Cell (2003) 113:587-596.
55. MILLER J, WILLIAMSON ED, LAKEY JH et al.: Macromolecular organisation of recombinant Yersinia pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol. Med. Microbiol. (1998) 21:213-221.
56. JONES SM, GRIFFIN KF, HODGSON I, WILLIAMSON ED: Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine (2003) 21:3912-3918.
57. WILLIAMSON ED, ELEY SM, STAGG AJ et al.: A single dose sub-unit vaccine protects against pneumonic plague. Vaccine (2001) 19:566-571.
58. WILLIAMSON ED, ELEY SM, STAGG AJ et al.: A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunised animals against pneumonic plague. Vaccine (1997) 15:1079-1084.
59. TITBALL RW, WILLIAMSON ED: Second and third generation plague vaccines. Adv. Exp. Med. Biol. (2003) 529:397-406.
60. NAKAJIMA R, MOTIN VL, BRUBAKER RR: Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect. Immun. (1995) 63:3021-3029.
61. NAKAJIMA R, BRUBAKER RR: Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect. Immun. (1993) 61:23-31.
62. SING A, ROST D, TVARDOVSKAIA N et al.: Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J. Exp. Med. (2002) 196:1017-1024.
63. NEDIALKOV YA, MOTIN VL, BRUBAKER RR: Resistance to lipopolysaccharide mediated by the Yersinia pestis V antigen-polyhistidine fusion peptide: amplification of interleukin-10. Infect. Immun. (1997) 65:1196-1203.
64. GREEN M, ROGERS D, RUSSELL P et al.: The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Immunol. Med. Microbiol. (1999) 23:107-113.
65. GROSFELD H, COHEN S, BINO T et al.: Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect. Immun. (2003) 71(1):374-383.
66. WILLIAMSON ED, BENNETT AM, PERKINS SD et al.: Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine (2002) 20:2933-2941.
67. BENNETT AM, PHILLPOTTS RJ, PERKINS SD, JACOBS SC, WILLIAMSON ED: Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine (1999) 18:588-596.
68. GARMORY HS, LEUSEN D, BROWN KA, TITBALL RW: Protection against plague afforded by immunisation with DNA optimised for expression of the Yersinia pestis V antigen. Vaccine (2004) (In Press).
69. OYSTON PCF, WILLIAMSON ED, LEARY SEC et al.: Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against Plague. Infect. Immun. (1995) 63:563-568.
70. BULLIFENT HL, GRIFFIN KF, JONES SM et al.: Antibody responses to Yersinia pestis F1-antigen expressed in Salmonella typhimurium aroA from in vivo-inducible promoters. Vaccine (2000) 18:2668-2676.
71. OSORIO JE, POWELL TD, FRANK RS et al.: Recombinant raccoon pox vaccine protects mice against lethal plague. Vaccine (2003) 21:1232-1238.
72. GARMORY HS, GRIFFIN KF, BROWN KA, TITBALL RW: Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine (2003) 21:3051-3057.
73. LEARY SEC, GRIFFIN KF, GARMORY HS, WILLIAMSON ED, TITBALL RW: Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb. Pathog. (1997) 23:167-179.
74. ALPAR HO, EYLES JE, WILLIAMSON ED, SOMAVARAPU S: Intranasal vaccination against plague, tetanus and diphtheria. Adv. Drug Deliv. Rev. (2001) 51:173-201.
75. EYLES JE, SHARP GJ, WILLIAMSON ED, SPIERS ID, ALPAR HO: Intra nasal administration of poly-lactic acid microsphere coencapsulated Yersinia pestis subunits confers protection from pneumonic plague in the mouse. Vaccine (1998) 16:698-707.
76. EYLES JE, WILLIAMSON ED, SPIERS ID et al.: Generation of protective immune responses to plague by mucosal administration of microsphere coencapsulated recombinant subunits. J. Control Release (2000) 63:191-200.
77. SPIERS ID, ALPAR HO, EYLES JE et al.: Studies on the co-encapsulation, release and integrity of two subunit antigens: rV and rF1 from Yersinia pestis. J. Pharm. Pharmacol. (1999) 51:991-997.
78. SPIERS ID, EYLES JE, BAILLIE LWJ, WILLIAMSON ED, ALPAR HO: Biodegradable microparticles with different release profiles: Effect on the immune response after a single administration via intranasal and intramuscular routes. J. Pharm. Pharmacol. (2000) 52:1195-1201.
79. PRIOR JL, HITCHEN PG, WILLIAMSON ED et al.: Characterization of the lipopolysaccharide of Yersinia pestis. Microb. Pathog. (2001) 30:49-57.
80. SIMPSON WJ, THOMAS RE, SCHWAN TG: Recombinant capsular antigen (fraction 1) from Yersinia pestis induces a protective antibody response in BALB/c mice. Am. J. Trop. Med. Hyg. (1990) 43:389-396.
81. ANDREWS GP, STRACHAN ST, BENNER GE et al.: Protective efficacy of recombinant Yersinia outer proteins against bubonic plague caused by encapsulated and nonencapsulated Yersinia pestis. Infect. Immun. (1999) 67:1533-1537.
82. LEARY SEC, GRIFFIN KF, GALYOV EE et al.: Yersinia outer proteins (YOPS) E, K and N ate antigenic but non-protective compared to V antigen, in a murine model of bubonic plague. Microb. Pathog. (1999) 26:159-169.
83. NEMETH J, STRALEY SC: Effect of Yersinia pestis YopM on experimental plague. Infect. Immun. (1997) 65:924-930.
84. ANDERSON GWJ, LEARY SEC, WILLIAMSON ED et al.: Recombinant V-antigen protects mice against pneumonic and bubonic plague against F1 capsule positive and negative strains of Y. pestis. Infect. Immun. (1996) 64:4580-4585.